Lipid Accumulation Product is Related to Metabolic Syndrome in Women with Polycystic Ovary Syndrome

Abstract

Purpose:

Metabolic disturbances are common features of polycystic ovary syndrome (PCOS), which possibly enhance the risk of diabetes and cardiovascular disease. Lipid accumulation product (LAP) is an emerging cardiovascular risk factor. The aim of this study was to explore the ability of LAP to identify metabolic syndrome (MS) in PCOS women.

Methods:

In a cross-sectional study, anthropometric, biochemical and clinical parameters were measured in 105 PCOS women. Receiver operating characteristic (ROC) analysis was used to find out the cut-off points of LAP to predict MS. MS was categorized according to International Diabetes Federation (IDF) criteria.

Results:

The prevalence of MS was 43.8% in this study. PCOS women with MS had significantly higher LAP levels compared to those without MS. LAP was highly correlated with components of MS. ROC analysis showed that LAP was a significant discriminator for MS in PCOS women, and the optimal cutoff point of LAP to predict MS was 54.2 (93.3% sensitivity, 96.7% specificity).

Conclusions:

LAP seems to be associated with MS and has a strong and reliable diagnostic accuracy for MS in PCOS women.

Key words

polycystic ovary syndrome - metabolic syndrome - lipid accumulation product

• References

• 1 Azziz R, Woods KS, Reyna R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749
• 2 Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236
• 3 Homburg R. Polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2008; 22: 261-274
• 4 Dunaif A, Xia J, Book CB et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801-810
• 5 Gambineri A, Pelusi C, Vicennati V et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002; 26: 883-896
• 6 Lo JC, Feigenbaum SL, Yang J et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1357-1363
• 7 Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91: 492-497
• 8 Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309-314
• 9 Rossi B, Sukalich S, Droz J et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93: 4780-4786
• 10 Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 2005; 5: 26
• 11 Kahn HS. The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. Diabetes Care 2006; 29: 151-153
• 12 Wehr E, Gruber HJ, Giuliani A et al. The lipid accumulation product is associated with impaired glucose tolerance in PCOS women. J Clin Endocrinol Metab 2011; 96: E986-E990
• 13 Taverna MJ, Martinez-Larrad MT, Frechtel GD et al. Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. Eur J Endocrinol 2011; 164: 559-567
• 14 Tellechea ML, Aranguren F, Martinez-Larrad MT et al. Ability of lipid accumulation product to identify metabolic syndrome in healthy men from Buenos Aires. Diabetes Care 2009; 32: e85
• 15 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
• 16 Cussons AJ, Watts GF, Burke V et al. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 2008; 23: 2352-2358
• 17 Cheung LP, Ma RC, Lam PM et al. Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Hum Reprod 2008; 23: 1431-1438
• 18 Verit FF. The prevalence of metabolic syndrome in clomiphene citrate resistant polycystic ovary syndrome. Gynecol Endocrinol 2012; 28: 365-369
• 19 Bhattacharya SM. Prevalence of metabolic syndrome in women with polycystic ovary syndrome, using two proposed definitions. Gynecol Endocrinol 2010; 26: 516-520
• 20 Ni RM, Mo Y, Chen X et al. Low prevalence of the metabolic syndrome but high occurrence of various metabolic disorders in Chinese women with polycystic ovary syndrome. Eur J Endocrinol 2009; 161: 411-418
• 21 Oh JY, Sung YA, Lee HJ et al. Optimal waist circumference for prediction of metabolic syndrome in young Korean women with polycystic ovary syndrome. Obesity (Silver Spring) 2010; 18: 593-597
• 22 Despres JP, Lemieux I, Bergeron J et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039-1049
• 23 Wild S, Pierpoint T, McKeigue P et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52: 595-600
• 24 Wiltgen D, Benedetto IG, Mastella LS et al. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Hum Reprod 2009; 24: 1726-1731
• 25 Wang F, Wu S, Song Y et al. Waist circumference, body mass index and waist to hip ratio for prediction of the metabolic syndrome in Chinese. Nutr Metab Cardiovasc Dis 2009; 19: 542-547